Active-ingredient Dossier
Ondansetron Hydrochloride Dihydrate
Active-ingredient Dossier for Ondansetron Hydrochloride Dihydrate (selective 5-ht3 antagonist). Australian brands, products, PBS listings, PBAC outcomes…
- Brand: Ondansetron Kabi
- Brand: ONDANSETRON-AFT
- Brand: ONDANSETRON-DRLA
- Therapeutic area: Gastroenterology
- Therapeutic area: Oncology
What is
Ondansetron Hydrochloride Dihydrate Ondansetron Hydrochloride Dihydrate is a selective 5-HT3 antagonist.
Australian brands containing
Ondansetron Hydrochloride Dihydrate — ONDANSETRON VIATRIS — ZOFRAN — ONDANSETRON ACCORD — Ondansetron Kabi — ONDANSETRON-AFT — ONDANSETRON-Baxter — ONDANSETRON-DRLA — ONDANSETRON-WGR
Therapeutic areas
Ondansetron Hydrochloride Dihydrate is registered in gastroenterology (13 brands) and oncology (3 brands).
Sponsor landscape
The ingredient is marketed by nine sponsors including Ipca Pharma, Accord Healthcare, Dr Reddys Laboratories, Fresenius Kabi, Alphapharm, and AFT Pharmaceuticals.
PBS and regulatory activity
Two brands containing ondansetron hydrochloride dihydrate have PBS-listed items, with the latest PBS schedule date being 1 May 2026. The latest PBAC outcome on record is from 1 December 2022.